Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00977457 · ClinicalTrials.gov registry record · Phase 1
Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery
A Phase 1 study of Prostate Cancer, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 1,045
- Enrollment target
- 1
- Study location
NCT00977457 is a Phase 1 study of Prostate Cancer that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 1,045 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (72% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00977457, a Phase 1 study of Prostate Cancer, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1,045 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies the side effects and best way to perform genetic testing in predicting biomarkers of recurrence in patients with prostate cancer undergoing surgery. Collecting and storing samples of tissue, blood, and other body fluids from patients to test in the laboratory and collecting information about the patient's health and treatment may help doctors learn more about cancer and help predict the recurrence of prostate cancer
Conditions Studied
Interventions
- GENETIC gene expression analysis
- GENETIC polymerase chain reaction
- GENETIC DNA analysis
- GENETIC RNA analysis
- GENETIC DNA methylation analysis
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,045 participants |
| Start Date | 2007-11-26 |
| Est. Completion | 2026-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00977457
The ClinicalTrials.gov registry entry for NCT00977457 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 1,045 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (72% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00977457 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00977457 about?
NCT00977457 is a clinical study titled "Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery". This trial studies the side effects and best way to perform genetic testing in predicting biomarkers of recurrence in patients with prostate cancer undergoing surgery. Collecting and storing samples of tissue, blood, and other body fluids from patients to test in the laboratory and collecting inform...
What is the current status of trial NCT00977457?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1,045 participants. The study started on 2007-11-26. Estimated completion is 2026-07-08.
What conditions does trial NCT00977457 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00977457?
The interventions under investigation include: gene expression analysis (GENETIC), polymerase chain reaction (GENETIC), DNA analysis (GENETIC), RNA analysis (GENETIC), DNA methylation analysis (GENETIC).
Who is sponsoring clinical trial NCT00977457?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00977457 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.